Fourth, more validation effort is needed on additional subjects treated on a broader set of protocols (beyond CCCG‐ALL‐2015, COG AALL0232, COG AALL0331 and Total Therapy 16); until then, we cannot conclude TIMD4 expression level is a useful biomarker for prognosis in low‐risk childhood ALL. Here, TIMD4 is linked to acute lymphoblastic leukemia.